Business Context and Reporting Period
Company: Connect Biopharma Holdings Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 28, 2025
Context: The Company reported receiving a notification from the Nasdaq Stock Market regarding non-compliance with the Minimum Bid Price Requirement for its American Depositary Shares (ADSs).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a regulatory notice regarding stock listing status.
Material Changes
- Stock Price Deficiency: For the last 30 consecutive business days ending March 24, 2025, the closing bid price of the Company's ADSs was below the $1.00 minimum requirement under Nasdaq Listing Rule 5450(a)(1).
- Listing Status: The Company has been granted an initial 180-day compliance period to regain compliance, expiring on September 22, 2025.
- Trading Continuity: The notification has no immediate effect on the listing or trading of ADSs; they will continue to trade on the Nasdaq Global Market under the symbol "CNTB."
Outlook, Risks, and Management Commentary
- Compliance Path: To regain compliance, the ADSs must close at or above $1.00 for a minimum of 10 consecutive business days within the 180-day window.
- Contingency Plan: If the Company fails to regain compliance by September 22, 2025, it may be eligible for an additional 180-day period. This requires transferring to the Nasdaq Capital Market and meeting its initial listing standards (excluding the bid price requirement).
- Delisting Risk: If the Company cannot cure the deficiency or is deemed ineligible for the second period, Nasdaq may initiate delisting proceedings. The Company may appeal such a determination, though success is not assured.
- Management Action: The Company intends to monitor the bid price and consider available options to restore compliance.
Investor Verification Checklist
- Verify the current closing bid price of CNTB ADSs to assess proximity to the $1.00 threshold.
- Monitor the Company's progress toward achieving 10 consecutive days of trading above $1.00 before September 22, 2025.
- Review future filings for any announcements regarding a potential transfer to the Nasdaq Capital Market.
- Check for any subsequent press releases or 8-K/6-K filings detailing specific corporate actions (e.g., reverse stock splits) intended to address the bid price deficiency.